




Exhibit A


6. On May 31, 1998, FUSA sold its generic drug business to American Pharmaceutical Partners ("APP"). APP is a company incorporated in the state of Delaware, and is completely separate and distinct from FUSA, FHI and Astellas. APP has not been named as a defendant in this litigation.
7. The sale of FUSA's generic business to APP was an "arms length" transaction. It included the transfer of all equipment, personnel and records involved in manufacture and sale of every generic drug manufactured by FUSA. These drugs included: vinblastine sulfate; vancomycin hydrochloride; acyclovir sodium; dexamethasone sodium phosphate; doxorubicin hydrochloride; fluorouracil; gentamicin sulfate; atropine sulfate injection; and normal saline solution.
8. None of the drugs listed in the previous paragraph have been manufactured or sold by FUSA, FHI or Astellas since May 31, 1998. To my knowledge, no representation as to the price of the drugs listed in the previous paragraph were made by FUSA, FHI or Astellas since May 31, 1998, except to the extent such representations were necessary in connection with sales made prior to May 31, 1998.
9. None of the three entities (*i.e.*, FHI, FUSA, Astellas) has ever produced triamcinolone acetone under the category of J3301.

Further Affiant Sayeth Naught.



Stephen S. Knowles
Astellas US Holding, Inc.

SUBSCRIBED and sworn before me this 14th day of June, 2006



NOTARY

My commission expires _____

